MENU
GNMX
ETF ticker: BATS
PRICE
CHANGE
NET ASSETS

GNMX stock forecast, quote, news & analysis

The investment seeks capital appreciation... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
GNMX
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for GNMX with price predictions
Oct 21, 2026

GNMX sees its Stochastic Oscillator ascends from oversold territory

On October 20, 2026, the Stochastic Oscillator for GNMX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 2 instances where the indicator left the oversold zone. In 2 of the 2 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on GNMX as a result. In 5 of 5 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.

Following a +4.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where GNMX advanced for three days, in 11 of 11 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

The Aroon Indicator entered an Uptrend today. In 23 of 26 cases where GNMX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.

Bearish Trend Analysis

The 10-day RSI Indicator for GNMX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 4 similar instances where the indicator moved out of overbought territory. In 2 of the 4 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.

The Moving Average Convergence Divergence Histogram (MACD) for GNMX turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 2 similar instances when the indicator turned negative. In 2 of the 2 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNMX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 50%.

GNMX broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Guardant Health (NASDAQ:GH), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks capital appreciation. The fund is an ETF that seeks to meet its objective by having Corgi Strategies, LLC actively manage the fund and, under ordinary market conditions, invest at least 80% of its net assets (plus any borrowings for investment purposes) in a portfolio of companies materially involved in the research, development, and commercialization of genomics and precision medicine technologies that enable improved disease detection, identifying and grouping patients based on genetic, molecular, or clinical characteristics to guide treatment decisions, targeted therapies, and data-driven healthcare. It is non-diversified.

Market Cap

The average market capitalization across the Corgi Genomics & Precision Medicine ETF (GNMX) ETF is 28.55B. The market cap for tickers in the group ranges from 58.36M to 256.61B. TMO holds the highest valuation in this group at 256.61B. The lowest valued company is CRBU at 58.36M.

High and low price notable news

The average weekly price growth across all stocks in the Corgi Genomics & Precision Medicine ETF (GNMX) ETF was 25%. For the same ETF, the average monthly price growth was 49%, and the average quarterly price growth was 345%. MYGN experienced the highest price growth at 34%, while GRAL experienced the biggest fall at -5%.

Volume

The average weekly volume growth across all stocks in the Corgi Genomics & Precision Medicine ETF (GNMX) ETF was 2%. For the same stocks of the ETF, the average monthly volume growth was -5% and the average quarterly volume growth was -7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 56
Price Growth Rating: 41
SMR Rating: 79
Profit Risk Rating: 86
Seasonality Score: 12 (-100 ... +100)
View a ticker or compare two or three
GNMX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of therapeutic protein delivery technology

Category Health

Category
Health
Address
Corgi ETF Trust I8 THE GREEN STE B
Phone
N/A
Web
N/A
GNMX sees its Stochastic Oscillator ascends from oversold territory